BRAF and lung carcinoma: We observed that using the VE1 antibody for IHC analysis afforded highly sensitivity and specificity to detect BRAF V600E-mutated lung ADCs in tissues from primary lung cancer, metastatic tumors, or malignant pleural effusion cell blocks.